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Abstract
Background: The natural (i.e. unvaccinated population) attack rate of an infectious disease is an important
parameter required for understanding disease transmission. As such, it is an input parameter in infectious disease
mathematical models. Influenza is an infectious disease that poses a major health concern worldwide and the
natural attack rate of this disease is crucial in determining the effectiveness and cost-effectiveness of public health
interventions and informing surveillance program design. We estimated age-stratified, strain-specific natural attack
rates of laboratory-confirmed influenza in unvaccinated individuals.
Methods: Utilizing an existing systematic review, we calculated the attack rates in the trial placebo arms using a
random effects model and a meta-regression analysis (GSK study identifier: 117102).
Results: This post-hoc analysis included 34 RCTs (Randomized Control Trials) contributing to 47 influenza seasons
from 1970 to 2009. Meta-regression analyses showed that age and type of influenza were important covariates. The
attack rates (95% CI (Confidence Interval)) in adults for all influenza, type A and type B were 3.50% (2.30%, 4.60%),
2.32% (1.47%, 3.17%) and 0.59% (0.28%, 0.91%) respectively. For children, they were 15.20% (11.40%, 18.90%), 12.27%
(8.56%, 15.97%) and 5.50% (3.49%, 7.51%) respectively.
Conclusions: This analysis demonstrated that unvaccinated children have considerably higher exposure risk than
adults and influenza A can cause more disease than influenza B. Moreover, a higher ratio of influenza B:A in
children than adults was observed. This study provides a new, stratified and up to-date natural attack rates that can
be used in influenza infectious disease models and are consistent with previous published work in the field.
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Background
Infectious diseases are a major cause of morbidity and
mortality worldwide [1]. The main focus for research on
infectious diseases is to improve disease control and ul-
timately eradicate the infection from the population [2].
Mathematical models of infectious diseases are import-
ant for studying the impact of various interventions on
disease outcome. Such investigations allow the imple-
mentation of targeted control measures, optimizing the
use of limited resources [2].
The validity of a model is highly dependent on the
validity of the input parameters. These models require
information on parameters describing the population
under study, disease transmission as well as parameters
describing the health outcomes of infection. Lack of reli-
able data complicates the development of models and
new data needs to be collected or analyzed or the model
itself needs to be fitted to available data to estimate in-
put parameters [3].
Influenza is an infectious disease that poses a major
health concern all over the world. The total economic bur-
den of influenza in the United States has been estimated
as $87.1 billion [4]. Developing mathematical models for
influenza can be used to determine how to mitigate dis-
ease. The attack rate of the influenza virus is crucial for
these models and a difficult parameter to obtain.
Generally, influenza epidemic infection rates are ob-
tained from influenza-like illness (ILI), surveillance data
and serological surveys [5]. In a static (e.g. decision tree)
model, the attack rate is often used directly as an input
parameter, whereas in a dynamic transmission model, it
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is used to calibrate, or calculate directly, the force of in-
fection. Whether static or dynamic, it is most preferable
to use the “natural attack rate”, that is, the attack rate
within the unvaccinated portion of the population. This
is a more “universal” quantity, since it is not as strongly
dependent on the population vaccine uptake, though it
is still coupled through herd immunity.
Turner et al. used age-specific attack rates of influenza
in an economic evaluation based on rates derived from
placebo-controlled trials of influenza vaccines and antivirals
[6]. The incidence of symptomatic laboratory-confirmed in-
fluenza cases in each placebo arm was used to estimate the
corresponding attack rates for each subgroup using a ran-
dom effects model. Overall, the attack rate was 6.55%
(range: 0 to 20%) for adults and 19.21% (range: 10 to 35%)
for children. All trials except one were in the US and
spanned eight influenza epidemics during the period
1984 through 1997-1998. These attack rates were not
adjusted for confounders and also were not stratified by
strain of influenza.
The objective of this study was to estimate the attack
rate of influenza stratified by both age and influenza
strain (A and B) for unvaccinated individuals measured by
laboratory-confirmed PCR (Polymerase Chain Reaction)
and/or culture.
Methods
This study (GSK study identifier: 117102) is a post-hoc
analysis of a published systematic review [7]. The full
methods have been published [7,8] and the protocol was
registered in the PROSPERO database (CRD42012001926).
Eligibility criteria
Healthy children, adults or the elderly were chosen as
the population of interest. All vaccine types were included:
trivalent influenza vaccines (TIV), live-attenuated influ-
enza vaccines (LAIV), and bivalent vaccines. Randomized
controlled trials (RCTs) or quasi-RCTs, written in English,
comparing influenza vaccine with placebo and reporting
data on the primary outcomes were included. The primary
outcome used was laboratory-confirmed influenza by PCR
and/or culture [7]. The secondary outcome included hae-
magluttination inhibition (HAI) assay alone or in combin-
ation with PCR and/or culture.
Information sources and search
Medical subject headings (MeSH) and text words re-
lated to influenza vaccination were used in the literature
search strategies. MEDLINE, EMBASE and Cochrane
Central Register of Controlled Trials were searched by
an experienced librarian. This was supplemented by search-
ing for trial protocols through metaRegister (http://www.
controlled-trials.com/mrct/), which allows the searching
of multiple trial protocol registries simultaneously. The
reference lists of included studies and relevant reviews
were scanned to ensure all studies were captured. Au-
thors of studies were contacted for additional informa-
tion, as necessary.
Study selection process
Online proprietary systematic review software Synthesi.SR
(http://knowledgetranslation.ca/sysrev/login.php), available
through the Li Ka Shing Knowledge Institute of St.
Michael’s hospital was used to screen citations and full-
text articles that were identified through the literature
search. After a team calibration exercise, the Synthesi.SR
program was used to screen citations and full-text arti-
cles. Each citation and full-text article was screened by
two reviewers independently.
Data items
The study characteristics abstracted were as follows: year
of conduct, sample size, country of conduct, setting, viral
strain(s) detected (strain A or B), age of study population
(mean and standard deviation), infection detection method
(PCR, viral culture, HAI), number of confirmed influenza
infections in the placebo arm and the total number of pa-
tients in the placebo arm.
Synthesis of included studies
The data was first summarized descriptively. The natural
attack rate was computed using the following formula:
number of influenza cases/number of subjects in the pla-
cebo arm × 100%, as per the methods in Turner et al. [6].
The overall natural attack rate of influenza for all unvac-
cinated individuals was derived using a random effects
model which allows for within and between study variance
[6]. Separate analyses were conducted for children and
adults (children: <18 years, Adults: ≥18 years), strain of in-
fluenza confirmed by laboratory testing (strain A or B),
the type of test used for laboratory confirmation (PCR
and/or culture vs. HAI testing alone or in combination
with PCR or culture). Time trends for attack rates were
observed through forest plots.
Meta-regression analysis
Important covariates that would influence the natural at-
tack rate of influenza were identified a priori. They were
age group, geographical region where the study was con-
ducted, type of laboratory-confirmed influenza detected
(all influenza, strain A and strain B), type of test used to
confirm infection (PCR and/or culture vs. HAI testing
alone or in combination with PCR or culture) and the year
of influenza season. Univariate analyses were conducted on
these covariates to determine their statistical significance.
Based on those results, meta-regression analysis was per-
formed on statistically significant covariates.
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It is not always preferred to run all possible covariates
in a meta-regression model as it would reduce statistical
power of the results and lead to larger confidence intervals.
The total number of covariates was constrained so that
there were enough studies per outcome [9]. Additionally,
statistical heterogeneity was tested using the I2 statistic
[10]. If high heterogeneity was observed, meta-regression
analysis was conducted. All statistical analyses were con-
ducted using R version 2.1.
Results
The systematic review informing this analysis yielded
1356 citations [7]. A total of 34 RCTs and 1 companion
report fulfilled the inclusion criteria (Figure 1). These 34
trials contributed to 47 influenza seasons from 1970 to
2009 including 94,821 participants. Reasons for exclusion,
study characteristics, and patient characteristics are re-
ported in detail elsewhere [7]. The trials were conducted
in North America (22/34), Europe (4/34), Australia (1/34)
and a mixture of multi-site trials in North America,
Europe, South America, Asia (7/34).
From the 47 influenza seasons identified, 37 reported
on the primary outcome (laboratory confirmed influenza
by PCR and/or culture) and all 47 reported on the sec-
ondary outcome (laboratory confirmed influenza by HAI
assay alone or in combination with PCR and/or culture).
From the 37 influenza seasons that reported on the pri-
mary outcome, 34 reported on influenza A and 35 re-
ported on influenza B. From the 47 influenza seasons
that reported on the secondary outcome, 41 reported on
influenza A and 42 reported on influenza B. Attack rates
were calculated for all age groups separated by type of
influenza using a random effects model (Table 1). All
results are reported in the following format: point esti-
mate, 95% confidence interval [CI, (lower level, upper
level)]. For the primary outcome, the overall attack rate
was 7.86% (5.48%, 10.23%) for all influenza, 5.68% (3.71%,
7.65%) for strain A and 1.87% (1.02%, 2.72%) for strain B.
For the secondary outcome, an attack rate of 9.84%
(7.06%, 12.62%) was observed for all strains, 6.96% (4.49%,
9.42%) for strain A and 2.57% (1.45%, 3.70%) for strain B.
The results of the random effects model also demon-
strated high statistical heterogeneity the high I2 values.
Meta-regression analysis was conducted to reduce the
heterogeneity associated with the attack rate calcula-
tions. Age was considered an important covariate in nat-
ural attack rate. In order to confirm this with our data, a
meta-regression analysis was conducted with age stratifi-
cations. With the available data from the studies from
the systematic review, we were only able to separate ages
into two categories: adults and children. Limited number
of trials reported on the elderly population alone and
Figure 1 Study flow chart.
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most of them did not report the primary outcome. It
was difficult to use geography as a covariate since many
trials were multi-national in nature. Due to this limita-
tion, we did not include geography as a covariate in the
meta-regression.
Data was separated by primary and secondary out-
come and type of influenza to determine whether adults
and children experience different attack rates. The results
of the meta-regression analysis are shown in Table 2. For
all influenza, adults exhibit an attack rate of 4.4% and chil-
dren experienced an attack rate that was 11% higher than
adults. For influenza A, adults exhibited an attack rate of
3.4% and children experienced a higher attack rate than
adults by 8.8%. For influenza B, adults showed an attack
rate of 1.1% and children showed an attack rate that was
4.4% higher than that of adults. All analyses were statisti-
cally significant and suggested that a subgroup analysis by
age group is required for the primary outcome for all in-
fluenza, influenza A and B.
When a similar meta-regression was conducted on the
broader secondary outcome, higher attack rates were ob-
served overall. Results can be seen in Table 3. Adults, on
average, exhibited at attack rate of 5.8% for all influenza
with children experiencing a rate that is 13.9% higher
than that of adults. For influenza A, adults experienced
an attack rate of 4.2% with children having an attack rate
7.9% higher than adults. Attack rate of influenza B was
lower than that of influenza A, with adults exhibiting an
attack rate of 1.4% and children having an attack rate
that is 5.6% higher than that of adults. These analyses
were all statistically significant. The trends of higher attack
rates for children than adults, and higher attack rates for
strain A than strain B were also present when analyzing
the secondary outcome.
Since we confirmed that age and type of influenza were
important covariates for natural attack rates, we then con-
ducted subgroup analysis by age group (adults and chil-
dren) and type of influenza (all, type A and type B) for the
primary outcome (Table 4). The overall attack rate for
adults for all influenza was 3.50% (2.30%, 4.60%) and when
separated by type, 2.32% (1.47%, 3.17%) for influenza A
and 0.59% (0.28%, 0.91%) for influenza B. For children, the
overall attack rate was 15.20% (11.40%, 18.90%) for all in-
fluenza. When stratified by type, 12.27% (8.56%, 15.97%)
for influenza A and 5.50% (3.49%, 7.51%) for influenza B.
Trials that reported outcomes specifically on adults and
children were included in this analysis and trials that re-
ported on mixed populations were excluded. Even with
the sub group analysis by age and type of influenza we still
observed high I2 values.
Table 1 Meta-analysis results comparing primary outcome (RT-PCR and/or culture) with secondary outcome (RT-PCR
and/or culture and/or HAI assay) for all ages
Type of influenza # of influenza seasons Sample size
(placebo group)
# of influenza cases
(placebo group)
Natural attack rate %
(lower 95% CI, upper 95% CI)
I2
Primary outcome (PCR and/or viral culture)
All 37 39115 1774 7.86 (5.48, 10.23) 99.86%
Influenza A 34 38360 1303 5.68 (3.71, 7.65) 99.69%
Influenza B 35 38854 491 1.87 (1.02, 2.72) 99.87%
Secondary outcome (PCR and/or viral culture and/or HAI assay)
All 47 41212 2055 9.84 (7.06, 12.62) 99.77%
Influenza A 41 40074 1505 6.96 (4.49, 9.42) 99.80%
Influenza B 42 40568 536 2.57 (1.45, 3.70) 99.93%
Abbreviations: CI confidence interval, HAI haemagglutination inhibition assay, RT-PCR reverse transcription polymerase chain reaction.
Table 2 Meta-regression for primary outcome
Estimate Standard error P-value
Influenza A and B
(Intercept) 0.044 0.012 0.0012
Children vs. Adults 0.110 0.019 <0.0001
Influenza A
(Intercept) 0.034 0.011 0.005
Children vs. Adults 0.088 0.018 <0.0001
Influenza B
(Intercept) 0.011 0.0055 0.046
Children vs. Adults 0.044 0.009 <0.0001
Table 3 Meta-regression for secondary outcome
Estimate Standard error P-value
Influenza A and B
(Intercept) 0.058 0.018 0.0024
Children vs. Adults 0.139 0.028 <0.0001
Influenza A
(Intercept) 0.042 0.018 0.0225
Children vs. Adults 0.079 0.0279 0.0074
Influenza B
(Intercept) 0.014 0.015 0.375
Children vs. Adults 0.056 0.024 0.025
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The forest plot for influenza A infections in children
and adults for the primary outcome can be seen in
Figure 2A and B respectively. The forest plot for influ-
enza B for children and adults can be seen in Figure 3A
and B respectively. Generally, no time trends were ob-
served in the attack rate for adults or children for each
type of influenza.
Discussion
This study estimated the natural attack rate of influenza
for unvaccinated children and adults using a post-hoc ana-
lysis of a previously conducted systematic review. This is
the best method to obtain such attack rates since currently
existing methods to obtain this data have a number of lim-
itations. First, estimating attack rates from surveillance
data provides attack rates as an aggregate of vaccinated
and unvaccinated individuals and not attack rates that are
specific to unvaccinated individuals that are presented
here. Second, extrapolating from surveillance data also ne-
cessitates estimating rates of primary care consultations
among influenza cases [5]. Third, even if there is an active
surveillance system looking for influenza, surveillance sys-
tems will be limited by under-reporting bias [11]. Finally,
it’s difficult to determine the size of the population under
surveillance which makes estimating rates of infection dif-
ficult as there is uncertainty around the denominator of
the ratio [11].
Although yearly influenza epidemics can seriously affect
all age groups, children younger than two years of age and
adults over 65 exhibit higher rates of disease [12]. Further,
contact pattern studies suggest that children are more vul-
nerable to infection due to their relatively more frequent
and longer intimate contacts with members of their age
group [13]. Therefore, age is believed to be important in
the natural attack rate of influenza. Geography dictates
contact patterns and seasonality which is known to be a
driver in severity of influenza [14]. Outbreaks of seasonal
influenza follow largely predictable seasonal patterns and
in temperate climate zones seasonal influenza epidemic
lasts from six to ten weeks and in tropical zones seasonal
patterns are less pronounced with more than one peak of
infection [15]. Thus, geography is also an important con-
sideration with regards to natural attack rate. With respect
to the two main types of influenza in circulation, influenza
A contributes to greater annual epidemics and infrequent
yet more-devastating pandemics than influenza B [16].
Therefore, it’s important to distinguish between these two
types of influenza types. As the sensitivity of various
laboratory methods for detecting influenza can yield dif-
ferent results, this was also included as an important co-
variate. Since yearly differences in influenza are seen from
season to season, the year of study conduct was also con-
sidered an important covariate. Therefore, age group, geo-
graphical region, type of laboratory-confirmed influenza
detected, type of test used to confirm detection and the
year of influenza season were all considered important co-
variates of natural attack rate in our study.
Meta-regression analyses conducted here showed that
age group and type of influenza are important covariates
in natural attack rates. For adults, an attack rate of 3.50%
(2.30%, 4.60%) was observed for all influenza strains.
When stratified by type, an attack rate of 2.32% (1.47%,
3.17%) was observed for influenza A and a rate of 0.59%
(0.28%, 0.91%) was observed for strain B. For children, the
overall attack rate was 15.20% (11.40%, 18.90%) and when
stratified, a rate of 12.27% (8.56%, 15.97%) was seen for
strain A and 5.50% (3.49%, 7.51%) was seen for strain B.
The weighted sum of the stratified rates may not add up
to the aggregate rates as some studies reported results for
both strains of influenza. Including HAI testing increased
the attack rate for all age groups and all types of influenza.
No general trends with time were observed for children
and adults for the primary outcome.
This study provides new, up to-date estimates of the
attack rate of influenza in children and adults separated
by type of influenza. Generally, our overall attack rates
for adults and children were lower than the attack rates
observed by Turner et al. [6]. The Turner analysis
included trials covering only 8 influenza seasons from
1984 to 1998 while our analysis covered 47 influenza
Table 4 Meta-analysis on primary outcome for adults and children




Natural attack rate %
(lower 95% CI, upper 95% CI)
I2
Adults
All 19 28748 627 3.50 (2.30, 4.60) 98.0%
Influenza A 19 28748 482 2.32 (1.47, 3.17) 97.90%
Influenza B 19 28748 150 0.59 (0.28, 0.91) 98.11%
Children
All 13 6187 1040 15.20 (11.40, 18.90) 94.0%
Influenza A 10 5432 714 12.27 (8.56, 15.97) 94.59%
Influenza B 11 5926 341 5.50 (3.49, 7.51) 94.69%
Abbreviations: CI confidence interval.
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seasons from 1970 to 2009. The primary outcome of
our studies was PCR and/or culture but the studies used
in the Turner analysis did not include PCR as a method
of detection. PCR is considered the most reliable diag-
nostic test for clinical practice with a higher accuracy of
detection [17]. Using culture as a method of detection
may miss influenza cases and the use of HAI testing
may lead to biased results [17]. This may explain why
the attack rates observed in the Turner analysis are
higher than the results we have obtained (6.55% for
adults versus 3.57% and 19.21% for children versus
14.22%). Our secondary outcome, which included HAI
testing, also showed an increase in attack rates for all
age groups and types of influenza which supports the
notion that higher attack rates are observed when HAI
testing is used as a method of detection. Furthermore,
the definition of children used by our study and by the
Turner study is quite different. In our study, children
were classified as <18 years while the Turner classified
them as <12 years. This may also attribute to the differ-
ences seen in attack rates when comparing between
studies. Influenza B is most prominent among older
children and young adults [18]. In line with this, our at-
tack rates for children exhibited a higher B:A ratio than
for adults. The B:A attack rate ratio for children was cal-
culated to be 0.45 while the ratio for adults was 0.25.
This further exemplifies that using this method to cal-
culate the natural attack rate does in fact reflect what is
observed in real life settings for seasonal influenza [18].
The strengths of our analysis over the Turner analysis
include the use of many trials covering more influenza
seasons, using a more accurate method of detection
(RT-PCR (Reverse Transcription Polymerase Chain Re-
action) and/or culture), adjusting for confounders that
Figure 2 Natural attack rate of influenza A in children (A) and adults (B) based on the primary outcome. Children were defined as <18
years and adults as ≥18 years. Abbreviations: CI confidence interval.
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affect the natural attack rate and providing strain-specific
natural attack rates for influenza.
Like any meta-analysis, our study has several limita-
tions. First, although we identified three RCTs reporting
data in the senior population, we were not able to derive
an attack rate for this population. Two out of the three
studies did not report on our primary outcome of inter-
est and the third study reported an attack rate of 0%.
Second, we faced an inability to calculate geography-
specific attack rates. Although it was decided a priori that
geography is an important covariate, the data did not sup-
port such an analysis. Although most of the trials were
conducted in North America, newer trials were multi-
centre in nature spanning over more than one continent,
making a geography-specific analysis difficult. Third, the
attack rates that are calculated here are attenuated by
community herd effects through vaccinated people in the
population. For countries with a low background vaccin-
ation rate, natural attack rates might be higher than what’s
reported here. As most of the studies in this analysis were
conducted in North America, the attack rates obtained
here would reflect the effects of herd immunity observe
through targeted vaccine coverage programs that are used
in this region. Furthermore, the attack rates observed in
this study are laboratory confirmed. A study by Glatman-
Freedman et al. have shown that in general, laboratory
confirmed attack rates are higher than clinical attack rates
which is an important consideration when using these
rates as model inputs [19]. Another limitation of this study
is that H1N1 and H3N2 strains were agglomerated as
strain A for analysis. The attack rates for these two types
for strain A are different from each other and thus lead to
Figure 3 Natural attack rate of influenza B in children (A) and adults (B) based on the primary outcome. Children were defined as <18
years and adults as ≥18years. Abbreviations: CI confidence interval.
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different health outcomes. Also, the severity of the in-
fluenza strains are known to be in the order of H3N2 >
B > H1N1 [18]. Therefore, one must be cautious when
applying the agglomerated attack rate presented here
for strain A to reflect H3N2 or H1N1 specifically. Al-
though we identified one study that focused on the H1N1
pandemic flu, Talaat et al. [20], it reported on adults and
elderly population together and therefore was not in-
cluded in the meta-regression of attack rate for adults.
Lastly, as this study is based on the results of an already
conducted systematic review, it is inherently limited by
the results of the systematic review. The systematic review
only focused on RCTs of vaccines and not antivirals (as
was done for the Turner et al. analysis). If the focus of the
systematic review was expanded to include antivirals, then
a large sample size would have been available for the at-
tack rate calculations and perhaps lead to reduced uncer-
tainty of the estimates that were derived from the analysis.
Influenza models are important tools in public health
decision-making, and natural attack rate of influenza is a
vital ingredient for such models, as either a direct input
parameter or a calibration target. It is imperative that ro-
bust data are used to inform these models so that they can
better predict disease transmission and also resource allo-
cation that is required to reduce the burden of illness. The
sophistication of mathematical models of disease transmis-
sion has increased in the last decade [21,22]; accordingly,
the need for valid, precise and accurate model inputs, such
as natural attack rate, is greater than ever. The over- or
under-estimation of these parameters can have significant
impact on estimating the burden of illness and can intro-
duce uncertainty in public health decision making.
Conclusions
In this study, we were able to determine important covari-
ates for natural attack rate of influenza and calculate age-
specific and strain-specific attack rates that would serve as
essential input parameters to an infectious disease model
for influenza. We believe that the use of robust and accur-
ate input parameters are key to reducing uncertainty asso-
ciated with infectious disease models and therefore would
make them more appealing in public health decision mak-
ing settings.
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